6 research outputs found

    Quantum-mechanical calculation of Stark widths of Ne VII n=3, Δn=0\Delta n=0 transitions

    Full text link
    The Stark widths of the Ne VII 2s3s-2s3p singlet and triplet lines are calculated in the impact approximation using quantum-mechanical Convergent Close-Coupling and Coulomb-Born-Exchange approximations. It is shown that the contribution from inelastic collisions to the line widths exceeds the elastic width contribution by about an order of magnitude. Comparison with the line widths measured in a hot dense plasma of a gas-liner pinch indicates a significant difference which may be naturally explained by non-thermal Doppler effects from persistent implosion velocities or turbulence developed during the pinch implosion. Contributions to the line width from different partial waves and types of interactions are discussed as well.Comment: 8 pages, 3 figures; accepted by Phys. Rev.

    Stark Broadening of the B III 2s-2p Lines

    Get PDF
    We present a quantum-mechanical calculation of Stark line widths from electron-ion collisions for the 2s1/22p1/2,3/22s_{1/2}-2p_{1/2,3/2}, lambda = 2066 and 2067 A, resonance transitions in B III. The results confirm the previous quantum-mechanical R-matrix calculations but contradict recent measurements and semi-classical and some semi-empirical calculations. The differences between the calculations can be attributed to the dominance of small L partial waves in the electron-atom scattering, while the large Stark widths inferred from the measurements would be substantially reduced if allowance is made for hydrodynamic turbulence from high Reynolds number flows and the associated Doppler broadening.Comment: 21 pages, 4 figures; to be published in Phys. Rev.

    Lyman series lines of HeII measured in a gas-liner pinch

    No full text
    International audienc

    The incidence and significance of anti-natalizumab antibodies - Results from AFFIRM and SENTINEL

    No full text
    Objective: To determine the incidence and clinical effects of antibodies that develop during treatment with natalizumab
    corecore